Petros Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Accrued Liabilities of $74.06 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $25.91K, a 57.47% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $48.15K, a 51.88% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$369.54K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $251.41K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $42.84K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$653.67K, a 137.88% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.73M.
- Petros Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$1.80M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $74.06K 10-Q · filed 2026-08-13 | -$295.49K derived: sum of 3 quarters · filed 2026-08-13 | -$44.08K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $48.15K 10-Q · filed 2026-05-13 | -$321.39K derived: sum of 2 quarters · filed 2026-05-13 | -$69.99K derived: sum of 3 quarters · filed 2026-05-13 | -$9.07K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$369.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$118.14K derived: sum of 2 quarters · filed 2026-04-15 | -$57.22K derived: sum of 3 quarters · filed 2026-08-13 | $42.84K 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | $251.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $312.33K derived: sum of 2 quarters · filed 2026-08-13 | $412.39K 10-Q · filed 2025-11-13 | $94.38K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $60.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $160.98K 10-Q · filed 2026-08-13 | -$157.02K derived: sum of 3 quarters · filed 2026-08-13 | -$707.62K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $100.06K 10-Q · filed 2026-05-13 | -$217.94K derived: sum of 2 quarters · filed 2026-05-13 | -$768.54K derived: sum of 3 quarters · filed 2026-05-13 | -$659.24K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$868.60K derived: sum of 2 quarters · filed 2026-04-15 | -$759.30K derived: sum of 3 quarters · filed 2026-04-15 | -$653.67K 10-K · filed 2026-04-15 | $1.10M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$550.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$441.30K derived: sum of 2 quarters · filed 2025-11-13 | -$335.67K 10-Q · filed 2025-11-13 | $1.18M 10-Q · filed 2024-11-13 | $1.16M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $109.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $214.93K 10-Q · filed 2025-08-14 | $1.31M 10-Q · filed 2024-08-14 | $1.71M derived: sum of 3 quarters · filed 2025-08-14 | $796.43K derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $105.64K 10-Q · filed 2025-05-15 | $965.92K 10-Q · filed 2024-05-15 | $1.60M derived: sum of 2 quarters · filed 2025-05-15 | $687.14K derived: sum of 3 quarters · filed 2025-05-15 | $1.86M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $581.51K derived: sum of 2 quarters · filed 2025-03-31 | $1.75M derived: sum of 3 quarters · filed 2025-03-31 | $1.73M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$909.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $260.10K derived: sum of 2 quarters · filed 2024-11-13 | $234.36K 10-Q · filed 2024-11-13 | -$613.45K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.14M 10-Q · filed 2024-08-14 | $296.09K derived: sum of 3 quarters · filed 2024-08-14 | $770.64K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$25.74K 10-Q · filed 2024-05-15 | -$873.55K derived: sum of 2 quarters · filed 2024-05-15 | -$399.01K derived: sum of 3 quarters · filed 2024-05-15 | -$1.90M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$847.82K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$373.27K derived: sum of 2 quarters · filed 2024-04-01 | -$1.88M derived: sum of 3 quarters · filed 2024-04-01 | -$1.80M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $474.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$1.03M derived: sum of 2 quarters · filed 2023-11-15 | -$954.61K 10-Q · filed 2023-11-15 | -$591.34K derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.43M 10-Q · filed 2023-08-14 | -$1.07M derived: sum of 3 quarters · filed 2023-08-14 | -$3.24M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $74.91K 10-Q · filed 2023-05-15 | $438.17K derived: sum of 2 quarters · filed 2023-05-15 | -$1.73M derived: sum of 3 quarters · filed 2023-05-15 | -$3.35M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $363.27K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | -$1.81M derived: sum of 2 quarters · filed 2023-03-31 | -$3.42M derived: sum of 3 quarters · filed 2023-03-31 | -$2.73M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$2.17M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$3.79M derived: sum of 2 quarters · filed 2022-11-15 | -$3.09M 10-Q/A · filed 2022-11-15 | -$2.83M derived: sum of 4 quarters · filed 2022-11-15 | ||||
| 2021-06-30 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$918.93K 10-Q · filed 2022-08-12 | -$658.16K derived: sum of 3 quarters · filed 2022-08-12 | -$1.44M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $698.50K 10-Q · filed 2022-05-16 | $959.27K derived: sum of 2 quarters · filed 2022-05-16 | $173.30K derived: sum of 3 quarters · filed 2022-05-16 | -$6.04M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $260.77K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$525.20K derived: sum of 2 quarters · filed 2022-03-31 | -$6.73M derived: sum of 3 quarters · filed 2022-03-31 | -$6.20M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$785.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$7.00M derived: sum of 2 quarters · filed 2021-11-15 | -$6.46M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$6.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$5.68M 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | $531.11K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |